Volume | 2,181,391 |
|
|||||
News | - | ||||||
Day High | 11.37 | Low High |
|||||
Day Low | 11.21 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Dynavax Technologies Corp | DVAX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
11.32 | 11.21 | 11.37 | 11.34 | 11.43 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
18,349 | 2,181,391 | $ 11.30 | $ 24,646,311 | - | 10.06 - 15.15 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:04:12 | formt | 10,622 | $ 11.34 | USD |
Dynavax Technologies Corp Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.48B | 130.61M | - | 232.28M | -6.39M | -0.05 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Dynavax Technologies News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical DVAX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 12.03 | 12.11 | 11.21 | 11.65 | 1,911,386 | -0.69 | -5.74% |
1 Month | 12.20 | 12.67 | 11.21 | 12.04 | 1,483,840 | -0.86 | -7.05% |
3 Months | 13.93 | 14.10 | 11.21 | 12.46 | 1,829,152 | -2.59 | -18.59% |
6 Months | 14.32 | 15.15 | 11.21 | 13.20 | 1,802,636 | -2.98 | -20.81% |
1 Year | 11.31 | 15.15 | 10.06 | 13.23 | 1,685,468 | 0.03 | 0.27% |
3 Years | 10.84 | 21.39 | 7.09 | 12.93 | 2,184,560 | 0.50 | 4.61% |
5 Years | 6.43 | 21.39 | 1.80 | 9.80 | 2,610,017 | 4.91 | 76.36% |
Dynavax Technologies Description
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of hepatitis B. Dynavax operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product. |